<DOC>
	<DOCNO>NCT01982864</DOCNO>
	<brief_summary>Aminoglycosides widely use treatment Gram-negative bacillus Staphylococcus aureus infection effectiveness low cost . Nevertheless , many aspect optimal use hemodialysis patient remain unsolved little know pharmacokinetics context . The current practice prescribe aminoglycosides particular patient consist give hemodialysis session half dose usually give patient normal renal function . However , theoretical consideration emerge clinical data suggest may beneficial dose regimen efficient peak concentration often attain occurrence ototoxicity nephrotoxicity still frequent .</brief_summary>
	<brief_title>Pharmacokinetics Aminoglycoside Hemodialysis Patients .</brief_title>
	<detailed_description>Recent evidence pharmacokinetics pharmacodynamics aminoglycosides strongly support administration aminoglycosides , rather , hemodialysis . Therapeutic drug monitoring use pharmacokinetic modeling currently use non-hemodialysis patient . However , PK tool employ suitable dialysis patient . For aminoglycosides , ratio peak Minimal Inhibitory Concentration ( MIC ) show parameter best correlate clinical efficacy , whilst prolong exposure high concentration relate either nephrotoxicity ototoxicity . Additionally , aminoglycosides mostly excrete unchanged drug urine clearance directly proportional glomerular filtration rate . The elimination half-life aminoglycosides approximately 1.5-3 hour adult normal renal function , greatly prolong 36-70 hour patient end-stage renal failure . In standard patient , aminoglycosides administer single dose , short time interval , obtain elevated blood peak concentration ( effective level ) . The next injection administer 24 hour , allow patient wash aminoside minimize residual blood concentration ( toxic level ) . The aim maximize peak concentration fair amount time ( repeat peak ) minimize overall drug exposure , responsible toxicity . For renal impaired patient , hypothesis hemodialyzer regard kidney . Thus , administration aminoside begin hemodialysis could lead profile elimination comparable observed normorenal patient . The research aim perform population pharmacokinetic ( POPPK ) study gentamicin give hemodialysis patient .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<criteria>age upper 18 year Patients hospitalize `` Service de Néphrologie Hémodialyse , Transplantations , CHU de Limoges '' Patients require chronic hemodialysis Patients require treatment aminoglycosides Patients willing give write informed consent participation study Patients affiliate French social security system equivalent Patients legal protection Patients unable unwilling provide inform consent legal protection Patients deprive liberty Contraindications gentamicin Pregnant breastfeed woman woman childbearing potential without efficient contraception ( base declaration ) Patients alter mental status psychiatric condition would interfere understand study Patients enrol another clinical trial test drug therapeutic strategy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Aminoglycosides</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>clinical pharmacokinetics</keyword>
	<keyword>pharmacokinetic modelling</keyword>
	<keyword>Bayesian estimation</keyword>
	<keyword>Necessity</keyword>
	<keyword>treatment</keyword>
	<keyword>gentamicin</keyword>
</DOC>